Testing the Effect of the InsuPad Device in Daily Life Conditions

Inclusion Criteria: * Male or female subjects aged 18 to 75 years (including 18 and 75 years old). * Type 1 or type 2 diabetes mellitus subjects with daily short-acting prandial insulin intake of \> 60 IU/day. * HbA1c \>=6.0% and =\< 8% * Use of short-acting prandial insulin analogues with multiple daily injections. The analog insulin brands to be used will be either insulin Lispro (Humalog, Liprolog) or insulin Aspart (NovoRapid) or insulin Glulisin (Apidra). * Subject agrees to sign consent form before any study-specific tests or procedures are to be performed. * Study subject is willing to perform at least 5 blood glucose measurements per day for at least 3 months, willing to comply with study procedures and to keep a detailed patient log book. Exclusion Criteria: * Excessive fibrosis, lipo-hypertrophy or eczema at injection sites. * Known gastro- or enteroparesis. * Unstable chronic disease other than diabetes mellitus (e. g. unstable angina pectoris, renal disease) for the last six months before study start. * Severe hypoglycaemic events requiring glucagon injection or glucose infusion within the last four weeks prior to study start. * Hypoglycaemia unawareness (Score \> 4 in the Hypoglycaemia Awareness Questionnaire) * Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior to study start * Any known life-threatening disease * Pregnant women, lactating women or women who intend to become pregnant during the observation period * Any other condition or compliance issues that might interfere with study participation or results * Subjects with heat sensitivity * Subjects involved in or planned to participate in other studies * Subjects who are incapable of contracting or under guardianship